Results 201 to 210 of about 96,522 (296)

Non-Suicidal Self-Injury and Exercise: Associations With Addiction. [PDF]

J Korean Med Sci
Lee HS, Rhee SJ, Kang DH, Min S, Hong M, Lee H, Ahn YM.   +6 more
europepmc   +1 more source

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma, Panagiota Tsitsi, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'o, Aparna Wagle Shukla, Roongroj Bhidayasiri, Tiago A. Mestre, Alvaro Sanchez Ferro, Alberto J. Espay, Michelle H.S. Tosin, Matej Skorvanek, Ioanna Markaki   +14 more
wiley   +1 more source

The Relationship Between Parental Psychological Control and Non-Suicidal Self-Injury in Adolescents: A Chain Mediation Model. [PDF]

Behav Sci (Basel)
Jiang X, Yue T, Wang S.
europepmc   +1 more source

The Hidden Burden of Hemifacial Spasm: A Systematic Review of Non‐Motor Symptoms

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary contractions of facial muscles. Traditionally regarded as a motor condition, HFS encompasses a spectrum of non‐motor symptoms that are often overlooked but significantly affect patients’ quality of life.
Miriam Carvalho Soares, Jacy Bezerra Parmera, Pedro Augusto Sampaio Rocha‐Filho   +2 more
wiley   +1 more source

Social contagion, the psychiatric symptom pool and non-suicidal self-injury. [PDF]

BJPsych Bull
Paris J.
europepmc   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Movement Disorders, EarlyView.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir‐McFarland, Lori Taylor, Glenn Morrison, Ted Yednock, Sanjay Keswani, Henk‐Andre Kroon   +15 more
wiley   +1 more source

Sleep characteristics and non-suicidal self-injury: unveiling the association in depressed adolescents. [PDF]

BMC Psychiatry
Liang J, Liu Y, Zhang T, Jia F, Hou C.
europepmc   +1 more source

Mental Health and Corresponding Interventions for Persons With Physical Disabilities: A Scoping Review

Medicine Advances, EarlyView.
This scoping review of 33 studies maps the landscape of mental health in persons with physical disabilities. It finds a high prevalence of depression, anxiety, posttraumatic stress disorder, and other psychological problems, but highlights significant heterogeneity across studies in sample size, measurement, and representativeness.
Hui Li, Mengqian Li, Hongguang Chen, Xueting Bai, Qi Qiu, Nanqi Fan, Xin Wu, Xing Wang   +7 more
wiley   +1 more source

Looking Within: Self-Concept, Cognitive Flexibility, and Emotion Regulation as Intrapersonal Discriminants of Non-Suicidal Self-Injury Cessation. [PDF]

J Clin Psychol
Herrick C, Melvin G, Skvarc D, Mildred H.   +3 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source